Insider · CIK 0001424620
John C Thomas
Files at DWTX (Dogwood Therapeutics, Inc.). First filing -, latest -.
John C Thomas files SEC Form 4 as director at DWTX (Dogwood Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John C Thomas has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | DWTX Dogwood Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 17, 2026 |
| Jun 27, 2025 | DWTX Dogwood Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +2,362 | $0.00 | $0 | 2,362 | Jul 1, 2025 |
| Jun 18, 2025 | DWTX Dogwood Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 210 | Jun 23, 2025 |
| Jun 18, 2025 | DWTX Dogwood Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 420 | Jun 23, 2025 |
Questions about John C Thomas
Answered from the filings on this page, as of the latest one.
Is John C Thomas buying or selling?
John C Thomas has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John C Thomas's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John C Thomas has 0.
Where does John C Thomas file Form 4?
John C Thomas has filed Form 4 at DWTX (Dogwood Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.